Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 1
2014 1
2016 3
2017 4
2018 3
2019 1
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
Kaplan JM, Sharma N, Dikdan S. Kaplan JM, et al. Int J Mol Sci. 2018 Jan 29;19(2):389. doi: 10.3390/ijms19020389. Int J Mol Sci. 2018. PMID: 29382128 Free PMC article. Review.
Hypoxia-inducible factor (HIF) plays a crucial role in the response to hypoxia at the cellular, tissue, and organism level. New agents under development to pharmacologically manipulate HIF may provide new and exciting possibilities in the treatment of
Hypoxia-inducible factor (HIF) plays a crucial role in the response to hypoxia at the cellular, tissue, and orga
Anemia management in chronic kidney disease and dialysis: a narrative review.
Collister D, Rigatto C, Tangri N. Collister D, et al. Curr Opin Nephrol Hypertens. 2017 May;26(3):214-218. doi: 10.1097/MNH.0000000000000317. Curr Opin Nephrol Hypertens. 2017. PMID: 28306566 Review.
PURPOSE OF REVIEW: This review describes the current state of anemia management with erythropoietin (EPO)-stimulating agents and iron supplementation in both chronic kidney disease and dialysis patients, with a focus on novel therapies. ...Phase …
PURPOSE OF REVIEW: This review describes the current state of anemia management with erythropoietin (EPO)-stimulating agents a …
Quel pourrait être le futur de la prise en charge de l’anémie dans l’insuffisance rénale chronique ?
Hermine O, Maciel T, Moura I. Hermine O, et al. Nephrol Ther. 2017 Jun;13(6S):6S7-6S10. doi: 10.1016/S1769-7255(18)30034-8. Nephrol Ther. 2017. PMID: 29463398 French.
During chronic renal failure, EPO deficiency is the main cause of anemia, but other factors such as iron deficiency and inflammatory syndrome are also involved. ...Thus, beside Epo treatment HIF and GDF-11 are potentially new therapeutic targets in …
During chronic renal failure, EPO deficiency is the main cause of anemia, but other factors such as iron deficie …
Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease.
Solak Y, Cetiner M, Siriopol D, Tarim K, Afsar B, Covic A, Kanbay M. Solak Y, et al. Blood Purif. 2016;42(2):160-7. doi: 10.1159/000446273. Epub 2016 Jun 18. Blood Purif. 2016. PMID: 27318465 Free article. Review.
Anemia seen in patients with chronic kidney disease is a particular form of 'anemia of chronic disease'. Although multifactorial in origin, erythropoiesis-stimulating agents (ESAs) and adjuvant iron therapy represent the primary tr
Anemia seen in patients with chronic kidney disease is a particular form of 'anemia of chronic
The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease.
Zhong H, Zhou T, Li H, Zhong Z. Zhong H, et al. Drug Des Devel Ther. 2018 Sep 18;12:3003-3011. doi: 10.2147/DDDT.S175887. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 30271115 Free PMC article.
INTRODUCTION: The purpose of this study was to analyze the effects of hypoxia-inducible factor (HIF) stabilizers on anemia in non-dialysis-dependent (NDD) and dialysis-dependent (DD) chronic kidney disease (CKD) patients. ...CONCLU …
INTRODUCTION: The purpose of this study was to analyze the effects of hypoxia-inducible factor (HIF) stabilizers on …
New options for the anemia of chronic kidney disease.
Coyne DW, Goldsmith D, Macdougall IC. Coyne DW, et al. Kidney Int Suppl (2011). 2017 Dec;7(3):157-163. doi: 10.1016/j.kisu.2017.09.002. Epub 2017 Nov 17. Kidney Int Suppl (2011). 2017. PMID: 30675430 Free PMC article. Review.
Anemia is a common complication of chronic kidney disease. Use of erythropoiesis-stimulating agents (ESA) has been a mainstay of treatment since 1990. ...In early clinical trials, these oral agents appear to be capable of replacing ESA therapy and mini
Anemia is a common complication of chronic kidney disease. Use of erythropoiesis-stimulating agents (ESA) has be
New Strategies for Anaemia Management in Chronic Kidney Disease.
Locatelli F, Del Vecchio L. Locatelli F, et al. Contrib Nephrol. 2017;189:184-188. doi: 10.1159/000450779. Epub 2016 Dec 12. Contrib Nephrol. 2017. PMID: 27951566 Review.
Erythropoiesis-stimulating agents (ESAs) and iron therapy are the standard of care for normocytic normochromic anaemia, which is a frequent comorbidity of patients with chronic kidney disease. ...Several attempts are being made to develop new drugs wit …
Erythropoiesis-stimulating agents (ESAs) and iron therapy are the standard of care for normocytic normochromic anaemia, which is a fr …
Iron therapy for managing anaemia in chronic kidney disease.
Macdougall IC. Macdougall IC. Curr Opin Nephrol Hypertens. 2018 Sep;27(5):358-363. doi: 10.1097/MNH.0000000000000436. Curr Opin Nephrol Hypertens. 2018. PMID: 29905580 Review.
PURPOSE OF REVIEW: Iron deficiency is a major contributory cause to the development of anaemia in chronic kidney disease (CKD), and thus, iron replacement therapy plays a critical role in the management of this condition. ...There is also …
PURPOSE OF REVIEW: Iron deficiency is a major contributory cause to the development of anaemia in chronic kidney dis
Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for primetime?
Macdougall IC. Macdougall IC. Curr Opin Nephrol Hypertens. 2022 Sep 1;31(5):399-405. doi: 10.1097/MNH.0000000000000813. Epub 2022 Jul 15. Curr Opin Nephrol Hypertens. 2022. PMID: 35894273 Review.
PURPOSE OF REVIEW: Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors have recently been developed as a new treatment for anemia associated with chronic kidney disease (CKD). ...SUMMARY: HIF prolyl hydroxylase inhibitors …
PURPOSE OF REVIEW: Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors have recently been developed as a new t …
Hypoxia-inducible factors and essential hypertension: narrative review of experimental and clinical data.
Afsar B, Afsar RE. Afsar B, et al. Pharmacol Rep. 2023 Aug;75(4):861-875. doi: 10.1007/s43440-023-00497-x. Epub 2023 May 21. Pharmacol Rep. 2023. PMID: 37210694 Review.
Hypoxia-inducible factor (HIFs) is a new class of drug developed for the management of anemia in chronic kidney disease (CKD) patients. ...Essential hypertension (HT) is an epidemic worldwide. HIFs play a role in many
Hypoxia-inducible factor (HIFs) is a new class of drug developed for the management of anemia in chron
17 results